In most CML patients (~95%), the BCR-ABL1 rearrangement arises from two major breakpoints, involving exons 13 or 14 of BCR and exon 2 of ABL1 (e13a2 and e14a2) [2]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.